WebJan 11, 2024 · After i.v.-injection of 64.3 μg/kg [3H]vitamin K1 and different doses of phenprocoumon (0.02 to 3 mg/kg) the [3H]vitamin K1 concentration in the liver decreases and the [3H] vitamin K1-2, 3-epoxide concentration increases dependent on the dose and the liver concentration of phenprocoumon. Phenprocoumon is used for the prophylaxis and treatment of thromboembolic disorders after heart bypass surgery and myocardial infarction (heart attack), long-term treatment of myocardial infarction with increased risk of thromboembolism, thrombophilia (abnormal blood clotting), antithrombin III … See more Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting blood thinner drug to be taken by mouth, and a derivative of coumarin. It acts as a vitamin K antagonist and … See more Phenprocoumon is contraindicated when bleeding risks exceed the potential benefits, for example in people with severe bleeding diathesis See more Mild cases of overdosing are characterised by minor bleeding and/or bruising; they can usually be controlled by reducing the dose. Taking a large amount of phenprocoumon … See more Mechanism of action Phenprocoumon is an inhibitor of the enzyme vitamin K epoxide reductase (VKOR). Vitamin K is needed to activate the coagulation factors II, VII, IX and X and the anticoagulation factors protein C and protein S, … See more The most common adverse effect is bleeding. It occurs in 5–25% of patients and ranges from harmless nosebleeds to life-threatening bleeding in the brain, gut wall, See more Due to its narrow therapeutic index, the fact that it can only be eliminated from the body after inactivation by the liver enzymes CYP2C9 and CYP3A4, and its high plasma protein binding … See more Phenprocoumon, a 4-hydroxycoumarin structurally similar to warfarin, is a white to off-white crystalline powder with a characteristic smell. It is practically insoluble in water, but soluble in chloroform, ethanol, methanol, and aqueous See more

Drug interactions with phenprocoumon and the risk of …

WebOct 31, 2024 · Phenprocoumon is not approved for sale by the U.S. Food and Drug Administration (FDA). Limited information indicates that anticoagulant maternal doses of … WebDrug overdose. Two cases of overdose of phenprocoumon have been reported, in a 57-year-old woman and a 76-year-old man, fatal in the former; there were multiple hemorrhages in both cases [34A ]. In patients who take a long time to recover from warfarin overdose the use of a long-acting superwarfarin [SED-15, 984] may be suspected; however, in ... iowa ortho dsm ia

Pharmakokinetik und Pharmakodynamik bei extrakorporaler ...

WebMar 16, 2024 · Background Determination of anticoagulant therapy is of pronounced interest in emergency situations. However, routine tests do not provide sufficient insight. This study was performed to investigate the impact of anticoagulants on the results of viscoelastometric assays using the ClotPro device. Methods This prospective, … WebNov 1, 2024 · Phenprocoumon is mainly indicated for use in stroke prevention in cases of atrial fibrillation, but is also used in the treatment and prophylaxis of thrombosis and embolism, in heart valve replacement, and for the long-time treatment of myocardial infarction when there is an increased risk of thromboembolic complications.6,7 Go to: … WebApr 18, 2024 · Phenprocoumon open country long range lightweight